Assessment of thyroid function in children aged 1-13 years with beta-thalassemia major

Iranian Journal of Pediatrics

Volumn 21, Issue 1, 2011, Pages 77-82

  Pirinççioǧlu, Ayfer Gözü ^a   Deniz, Turgay ^a   Gökalp, Deniz ^a   Beyazit, Nurcan ^a   Haspolat, Kenan ^a   Söker, Murat ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Beta thalassemia; Chelation therapy; Hypothyroidism; Iron overload; Splenectomy

Indexed keywords

DEFEROXAMINE; FERRITIN; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HYPOTHYROIDISM; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; THALASSEMIA MAJOR; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL;

EID: 79952904035     PISSN: 10184406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001;79(8):704-712.
2. Weatherall DJ, Clegg JB, editors. The Thalassemia Syndromes. 4th ed. Oxford: Blackwell Science. 2001; Pp: 121-392.
3. De Sanctis V, Roos M, Gasser T, et al. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassemia. J Pediatr Endocrinol Metab 2006;19(4):471-480.
4. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab 2000;13(6):651-656.
5. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for betathalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005;1054:186-195.
6. Ghavamzadeh A, Nasseri P, Eshraghian MR, et al. Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran. Bone Marrow Transplant 1998;22(12):1167-1169.
7. Sodani P, Isgro A, Gaziev J, et al. Purified Tdepleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010; 115(6):1296-1302.
8. Chern JP, Su S, Lin KH, et al. Survival, mortality and complications in patients with beta thalassemia major in northern Taiwan. Pediatr Blood Cancer 2007;48(5):550-554.
9. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003;3(1):23-34.
10. Malik SA, Syed S, Ahmed N. Frequency of hypothyroidism in patients of beta-thalassemia. Pak I Med Assoc 2010;60(1):17-29.
11. Srivatsa A, Arivatsa A. Assessment of adrenal endocrine function in Asian thalassemics. Indian Pediatr 2005;42(1):31-35.
12. Al-Elq AH, Al-Saeed HH. Endocrinopathies in patients with thalassemias. Saudi Med J 2004; 25(10):1347-1351.
13. Karamifar H, Shahriari M, Sadjadian N. Prevalence of endocrine complications in betathalassemia major in the Islamic Republic of Iran. East Mediterr Health J 2003;9(1-2):55-60.
14. Zervas A, Katopodi A, Protonotariou A, et al. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid 2002;12(2):151-154.
15. Aydinok Y, Darcan S, Polat A, et al. Endocrine complications in patients with beta-thalassemia major. J Trop Pediatr 2002;48(1): 50-54.
16. Baba K, Zantout MS, Azar ST. Endocrinologic Diseases in hemoglobinopathies. Endocrinologist 2009;19(1):44-47.
17. Mahraver A, Azarkeivan A, Faranoush M, et al. Endcrinopathies in patients with transfusiondepentent beta-thalassemia. Pediatr Hemat Oncol 2008;25(3):187-194.
18. Malik S, Syed S, Ahmed N. Complications in transfusion-dependent patients with betathalassemia major: a review. Pak J Med Sci 2009;25(4):678-682.
19. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassemia versus sicklecell disease. Br J Haematol 2006;135(4):574-582.
20. Agarwal MB. Advances in management of thalassemia (Editorial). Indian Pediatr 2004; 41(10):989-992.
21. Hershko C. Role of iron chelation therapy in Thalassemia major. Turk J Haematol 2002; 19(2):121-126.
22. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102(1):17-24.
23. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 2003;162(3):139-146.
24. Angelopoulos NG, Goula A, Rombopoulos G, et al. Hypoparathyroidism in transfusiondependent patients with beta-thalassemia. J Bone Miner Metabol 2006;24(2):87-93.
25. Miskin H, Yaniv I, Berant M, et al. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003;70(6):398-403.
26. De Sanctis V, De Sanctis E, Ricchieri P, et al. Mild subclinical hypothyroidism in thalassemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. Pediatr Endocrinol Rev 2008;6(suppl 1): 174-180.
27. Aruratanasirikul S, Wongcharnchailert M, Laosombat V, et al. Thyroid function in β-thalassemic children receiving hypertransfusions with suboptimal iron-chelating therapy. J Med Assoc Thai 2007;90(9):1798-1802.